177 related articles for article (PubMed ID: 8693619)
1. [The effect of salmeterol in the treatment of smokers with chronic obstructive lung disease].
Ulrik CS
Ugeskr Laeger; 1996 Jun; 158(25):3604-7. PubMed ID: 8693619
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.
Ulrik CS
Thorax; 1995 Jul; 50(7):750-4. PubMed ID: 7570409
[TBL] [Abstract][Full Text] [Related]
3. [efficacy and safety of salmeterol in long-term therapy in patients with chronic obstructive airway diseases].
Beeh KM; Wiewrodt R; Salem AE; Buhl R
Pneumologie; 2000 Jun; 54(6):225-31. PubMed ID: 10934892
[TBL] [Abstract][Full Text] [Related]
4. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
5. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma.
Busse WW; Casale TB; Murray JJ; Petrocella V; Cox F; Rickard K
Am J Manag Care; 1998 Nov; 4(11):1579-87. PubMed ID: 10338904
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD).
Boyd G; Morice AH; Pounsford JC; Siebert M; Peslis N; Crawford C
Eur Respir J; 1997 Apr; 10(4):815-21. PubMed ID: 9150318
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of salmeterol in stable COPD.
Kaushik ML; Kashyap S; Bansal SK; Sharma A
Indian J Chest Dis Allied Sci; 1999; 41(4):207-12. PubMed ID: 10661008
[TBL] [Abstract][Full Text] [Related]
9. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
10. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.
Taccola M; Bancalari L; Ghignoni G; Paggiaro PL
Monaldi Arch Chest Dis; 1999 Aug; 54(4):302-6. PubMed ID: 10546469
[TBL] [Abstract][Full Text] [Related]
11. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
[TBL] [Abstract][Full Text] [Related]
12. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
13. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease.
Cazzola M; Vinciguerra A; Di Perna F; Matera MG
Respir Med; 1998 Aug; 92(8):1012-6. PubMed ID: 9893768
[TBL] [Abstract][Full Text] [Related]
14. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Rennard SI; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K
Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
[TBL] [Abstract][Full Text] [Related]
15. [Salmeterol and prolonged treatment of asthma: international clinical data].
Bons J; Pappo M
Rev Mal Respir; 1992; 9 Suppl 1():R15-8. PubMed ID: 1350364
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of and tolerance to salmeterol compared to salbutamol in patients with bronchial asthma].
De Oliveira MA; Jardim JR; Faresin SM; Lucas SR; Nery LE
Rev Assoc Med Bras (1992); 1998; 44(3):169-75. PubMed ID: 9755543
[TBL] [Abstract][Full Text] [Related]
17. Quality of life changes in COPD patients treated with salmeterol.
Jones PW; Bosh TK
Am J Respir Crit Care Med; 1997 Apr; 155(4):1283-9. PubMed ID: 9105068
[TBL] [Abstract][Full Text] [Related]
18. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group.
Lundback B; Rawlinson DW; Palmer JB
Thorax; 1993 Feb; 48(2):148-53. PubMed ID: 8493629
[TBL] [Abstract][Full Text] [Related]
19. [Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction].
Vollmer M; Schmidt EW; Ulmer WT
Pneumologie; 1995 Oct; 49(10):528-34. PubMed ID: 8584522
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.
van Noord JA; de Munck DR; Bantje TA; Hop WC; Akveld ML; Bommer AM
Eur Respir J; 2000 May; 15(5):878-85. PubMed ID: 10853852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
